ES2075433T3 - Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn. - Google Patents

Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn.

Info

Publication number
ES2075433T3
ES2075433T3 ES91905554T ES91905554T ES2075433T3 ES 2075433 T3 ES2075433 T3 ES 2075433T3 ES 91905554 T ES91905554 T ES 91905554T ES 91905554 T ES91905554 T ES 91905554T ES 2075433 T3 ES2075433 T3 ES 2075433T3
Authority
ES
Spain
Prior art keywords
perfluorocarbon emulsion
tissue
subject
spin
oxygen tension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905554T
Other languages
English (en)
Inventor
Peter P Antich
Padmakar V Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of ES2075433T3 publication Critical patent/ES2075433T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

SE PRESENTAN COMPUESTOS ETIQUETADOS COMO 19F QUE SON UTILES EN METODOS DE FORMACION DE IMAGENES NMR Y EN ESPECTROSCOPIA. LOS COMPUESTOS COMPRENDEN UNA MOLECULA SENSORA QUE CONTIENE 19F, Y UN POLIMERO O SUBSTRATO DE TRANSPORTE, Y PUEDEN OPCIONALMENTE COMPRENDER TAMBIEN UNA MOLECULA SEPARADORA PARA SEPARAR LA MOLECULA SENSORA Y EL POLIMERO DE TRANSPORTE.
ES91905554T 1990-02-21 1991-02-21 Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn. Expired - Lifetime ES2075433T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/482,879 US5236694A (en) 1990-02-21 1990-02-21 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents

Publications (1)

Publication Number Publication Date
ES2075433T3 true ES2075433T3 (es) 1995-10-01

Family

ID=23917811

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905554T Expired - Lifetime ES2075433T3 (es) 1990-02-21 1991-02-21 Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn.

Country Status (9)

Country Link
US (3) US5236694A (es)
EP (1) EP0517788B1 (es)
JP (1) JPH05506432A (es)
AT (1) ATE125712T1 (es)
AU (1) AU641233B2 (es)
CA (1) CA2075953A1 (es)
DE (1) DE69111798T2 (es)
ES (1) ES2075433T3 (es)
WO (1) WO1991012824A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
GB9216843D0 (en) * 1992-08-07 1992-09-23 Cancer Res Inst Contrast agents for medical imaging
US5468467A (en) * 1993-04-23 1995-11-21 Bracco International B.V. Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
GB9325330D0 (en) * 1993-12-10 1994-02-16 Univ Toronto Fluorocyclodextrin drug delivery system
CA2223994A1 (en) * 1995-06-07 1996-12-19 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents and method therefor
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5678548A (en) * 1995-07-20 1997-10-21 The United States Of America As Represented By The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance
US5753207A (en) * 1995-08-21 1998-05-19 Beth Israel Deaconess Medical Center, Inc. Use of paramagnetic compounds to measure temperature and pH in vivo
US5828216A (en) * 1996-08-19 1998-10-27 The United States Of America As Represented By The Department Of Health And Human Services Gated RF preamplifier for use in pulsed radiofrequency electron paramagnetic resonance and MRI
AT409929B (de) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung
US6419174B1 (en) * 2000-08-18 2002-07-16 J. M. Huber Corporation Abrasive compositions and methods for making same
US6574497B1 (en) 2000-12-22 2003-06-03 Advanced Cardiovascular Systems, Inc. MRI medical device markers utilizing fluorine-19
NO20015802D0 (no) * 2001-11-28 2001-11-28 Amersham Health As Diagnostisk metode
JP2005531648A (ja) * 2002-04-11 2005-10-20 カルボマー インク 生体適合性物質およびプローブ類
AU2003234709A1 (en) * 2002-04-11 2003-10-27 Carbomer Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri
US6911457B2 (en) 2002-04-11 2005-06-28 Carbomer, Inc. Diabetes imaging probes
WO2004078990A1 (en) * 2003-02-28 2004-09-16 Carbomer, Inc. Halogenated emulsans
CA2560544C (en) 2004-01-16 2015-05-19 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
AU2005310986A1 (en) * 2004-11-12 2006-06-08 Bellus Health (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
DE102005005704B4 (de) 2005-02-03 2010-08-12 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Verwendung von Partikeln für die Ermittlung der lokalen Temperatur in organischen und nichtorganischen Körpern
CA2649294A1 (en) * 2006-04-14 2008-05-08 Celsense, Inc. Methods for assessing cell labeling
AU2007238586B2 (en) * 2006-04-14 2014-03-20 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
GB0711662D0 (en) * 2007-06-15 2007-07-25 Cancercure As Magnetic resonance guided cancer treatment system
JP5645658B2 (ja) * 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
US8093060B2 (en) * 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
EP2280736B1 (en) * 2008-05-02 2016-11-02 Celsense Inc. Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
EP2459235B1 (en) 2009-07-31 2014-04-23 Koninklijke Philips N.V. Perfluoro-t-butyl cyclohexane for use in imaging
CN103228297A (zh) * 2010-12-10 2013-07-31 默克专利股份公司 用于通过mri的靶向分子成像的由f-19核标记的适体
WO2012142670A1 (en) * 2011-04-20 2012-10-26 The University Of Queensland Nuclear magnetic resonance agent
JP6234064B2 (ja) * 2012-05-23 2017-11-22 キヤノン株式会社 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4817750B1 (es) * 1970-12-29 1973-05-31
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4640833A (en) * 1983-02-28 1987-02-03 Adamantech, Inc. Use of perfluorobromoalkyl ethers as X-ray contrast agents
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4558279A (en) * 1983-03-07 1985-12-10 University Of Cincinnati Methods for detecting and imaging a temperature of an object by nuclear magnetic resonance
US4612185A (en) * 1984-10-15 1986-09-16 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
JP2514340B2 (ja) * 1986-11-26 1996-07-10 森 武貞 修飾抗体
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US4914210A (en) * 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
AU2803289A (en) * 1987-10-27 1989-05-23 Fluoromed Pharmaceutical, Inc. Method of using fluorocarbons in nuclear magnetic resonance imaging
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
DE3834704A1 (de) * 1988-10-07 1990-06-07 Schering Ag Fluorsubstituierte benzolderivate
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5068098A (en) * 1990-06-11 1991-11-26 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy
US5196348A (en) * 1990-06-11 1993-03-23 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue

Also Published As

Publication number Publication date
AU641233B2 (en) 1993-09-16
WO1991012824A2 (en) 1991-09-05
US5236694A (en) 1993-08-17
EP0517788B1 (en) 1995-08-02
US5397562A (en) 1995-03-14
WO1991012824A3 (en) 1992-02-20
US5422094A (en) 1995-06-06
JPH05506432A (ja) 1993-09-22
DE69111798T2 (de) 1995-11-30
AU7453991A (en) 1991-09-18
CA2075953A1 (en) 1991-08-22
EP0517788A1 (en) 1992-12-16
ATE125712T1 (de) 1995-08-15
DE69111798D1 (de) 1995-09-07

Similar Documents

Publication Publication Date Title
ES2075433T3 (es) Compuestos marcados con 19f como agentes de formacion de imagenes y de espectroscopia por rmn.
Merboldt et al. Decrease of glucose in the human visual cortex during photic stimulation
US6370415B1 (en) Magnetic resonance imaging method
Calamante et al. Early changes in water diffusion, perfusion, T1, and T2 during focal cerebral ischemia in the rat studied at 8.5 T
Liu et al. Assessment of cerebral pO2 by EPR oximetry in rodents: effects of anesthesia, ischemia, and breathing gas
Matsumoto et al. MR assessment of changes of tumor in response to hyperbaric oxygen treatment
Mignion et al. Hexafluorobenzene in comparison with perfluoro‐15‐crown‐5‐ether for repeated monitoring of oxygenation using 19F MRI in a mouse model
Petersson et al. White matter injury after cerebral ischemia in ovine fetuses
Zhao et al. Tumor oxygen dynamics with respect to growth and respiratory challenge: investigation of the Dunning prostate R3327-HI tumor
Rupreht et al. Evaluation of the tibial tunnel after intraoperatively administered platelet‐rich plasma gel during anterior cruciate ligament reconstruction using diffusion weighted and dynamic contrast‐enhanced MRI
Sakoh et al. Prediction of tissue survival after middle cerebral artery occlusion based on changes in the apparent diffusion of water
Gyngell et al. Evolution of acute focal cerebral ischaemia in rats observed by localized 1H MRS, diffusion‐weighted MRI, and electrophysiological monitoring
ATE221208T1 (de) VERFAHREN ZUR ßIN-VIVOß-MESSUNG DER KONZENTRATION VON XENOBIOTISCHEN VERBINDUNGEN MITTELS MAGNETISCHER KERNRESONANZ
Sostman et al. Evaluation of BA1112 rhabdomyosarcoma oxygenation with microelectrodes, optical spectrophotometry, radiosensitivity, and magnetic resonance spectroscopy
Najafi et al. Longitudinal measurements of syrinx size in a rat model of posttraumatic syringomyelia
Jezzard et al. An in vivo model for functional MRI in cat visual cortex
Vallatos et al. Multiple boli arterial spin labeling for high signal‐to‐noise rodent brain perfusion imaging
Crémillieux et al. Online quantification of lactate concentration in microdialysate during cerebral activation using 1H-MRS and sensitive NMR microcoil
Lambers et al. Fiber-based lactate recordings with fluorescence resonance energy transfer sensors by applying an magnetic resonance-informed correction of hemodynamic artifacts
Felber et al. Localized proton and phosphorus magnetic resonance spectroscopy following electroconvulsive therapy
Kauppinen et al. Visual Activation in α‐Chloralose‐anaesthetized Cats Does Not Cause Lactate Accumulation in the Visual Cortex as Detected by [1HINMR Difference Spectroscopy
CA2327733C (en) Use of a hyperpolarized gas for mri detection of regional variations in oxygen uptake from the lungs
ATE395611T1 (de) Pulsfolge, kernspinresonanztomograph und bildgebungsverfahren
Venkatasubramanian et al. Characterization of the cerebral distribution of general anesthetics in vivo by two‐dimensional 19F chemical shift imaging
WO1999053332A1 (en) Use of a hyperpolarized gas for mri detection of regional variations in oxygen uptake from the lungs

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517788

Country of ref document: ES